 |
drug-information.ru |
|Digoxin Digoxin injection |
| Drugs search, click the first letter of a drug name: | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9 Home DigoxinGeneric Name: Digoxin Dosage Form: Injection, usp Digoxin DescriptionDigoxin is one of the cardiac (or digitalis) glycosides, a closely related group of drugs having in common specific effects on the myocardium. These drugs are found in a number of plants. Digoxin is extracted from the leaves ofDigitalis lanata. The term“digitalis” is used to designate the whole group of glycosides. The glycosides are composed of two portions: a sugar and a cardenolide (hence “glycosides”). Digoxin has the chemical name: 3β - [(O - 2,6 - Dideoxy - β - D - ribo - hexopyranosyl - (1→4) - O - 2,6 - dideoxy - β - D - ribo - hexopyranosyl - (1→4) - 2,6 - dideoxy - β - D - ribo - hexopyranosyl)oxy] - 12β,14 - dihydroxy - 5β - card - 20(22) - enolide, and the following structural formula:  C41H64O14 MW 780.94 Digoxin exists as odorless white crystals that melt with decomposition above 230°C. The drug is practically insoluble in water and in ether; slightly soluble in diluted (50%) alcohol and in chloroform; and freely soluble in pyridine. Digoxin Injection is a sterile solution for slow intravenous or deep intramuscular injection. Each mL contains Digoxin 250 mcg (0.25 mg), alcohol 0.1 mL, propylene glycol 0.4 mL, dibasic sodium phosphate, anhydrous 3 mg and citric acid, anhydrous 0.8 mg in Water for Injection. pH 6.7-7.3; citric acid and/or sodium phosphate added, if necessary, for pH adjustment. Dilution is not required. Digoxin - Clinical PharmacologyMechanism of ActionDigoxin inhibits sodium-potassium ATPase, an enzyme that regulates the quantity of sodium and potassium inside cells. Inhibition of the enzyme leads to an increase in the intracellular concentration of sodium and thus (by stimulation of sodium-calcium exchange) an increase in the intracellular concentration of calcium. The beneficial effects of Digoxin result from direct actions on cardiac muscle, as well as indirect actions on the cardiovascular system mediated by effects on the autonomic nervous system. The autonomic effects include: (1) a vagomimetic action, which is responsible for the effects of Digoxin on the sinoatrial and atrioventricular (AV) nodes; and (2) baroreceptor sensitization, which results in increased afferent inhibitory activity and reduced activity of the sympathetic nervous system and renin-angiotensin system for any given increment in mean arterial pressure. The pharmacologic consequences of these direct and indirect effects are: (1) an increase in the force and velocity of myocardial systolic contraction (positive inotropic action); (2) a decrease in the degree of activation of the sympathetic nervous system and renin-angiotensin system (neurohormonal deactivating effect); and (3) slowing of the heart rate and decreased conduction velocity through the AV node (vagomimetic effect). The effects of Digoxin in heart failure are mediated by its positive inotropic and neurohormonal deactivating effects, whereas the effects of the drug in atrial arrhythmias are related to its vagomimetic actions. In high doses, Digoxin increases sympathetic outflow from the central nervous system (CNS). This increase in sympathetic activity may be an important factor in digitalis toxicity. PharmacokineticsNote–The following data are from studies performed in adults, unless otherwise stated. AbsorptionComparisons of the systemic availability and equivalent doses for preparations of Digoxin are shown in Table 1:
*For example, 125 mcg Digoxin Tablets equivalent to 125 mcg Digoxin Elixir Pediatric equivalent to 100 mcg Digoxin Capsules equivalent to 100 mcg Digoxin Injection/IV. DistributionFollowing drug administration, a 6- to 8-hour tissue distribution phase is observed. This is followed by a much more gradual decline in the serum concentration of the drug, which is dependent on the elimination of Digoxin from the body. The peak height and slope of the early portion (absorption/distribution phases) of the serum concentration-time curve are dependent upon the route of administration and the absorption characteristics of the formulation. Clinical evidence indicates that the early high serum concentrations do not reflect the concentration of Digoxin at its site of action, but that with chronic use, the steady-state post-distribution serum concentrations are in equilibrium with tissue concentrations and correlate with pharmacologic effects. In individual patients, these post-distribution serum concentrations may be useful in evaluating therapeutic and toxic effects (see DOSAGE AND ADMINISTRATION, Serum Digoxin Concentrations). Digoxin is concentrated in tissues and therefore has a large apparent volume of distribution. Digoxin crosses both the blood-brain barrier and the placenta. At delivery, the serum Digoxin concentration in the newborn is similar to the serum concentration in the mother. Approximately 25% of Digoxin in the plasma is bound to protein. Serum Digoxin concentrations are not significantly altered by large changes in fat tissue weight, so that its distribution space correlates best with lean (i.e., ideal) body weight, not total body weight. MetabolismOnly a small percentage (16%) of a dose of Digoxin is metabolized. The end metabolites, which include 3β-digoxigenin, 3-keto-digoxigenin, and their glucuronide and sulfate conjugates, are polar in nature and are postulated to be formed via hydrolysis, oxidation, and conjugation. The metabolism of Digoxin is not dependent upon the cytochrome P-450 system, and Digoxin is not known to induce or inhibit the cytochrome P-450 system. ExcretionElimination of Digoxin follows first-order kinetics (that is, the quantity of Digoxin eliminated at any time is proportional to the total body content). Following intravenous administration to healthy volunteers, 50% to 70% of a Digoxin dose is excreted unchanged in the urine. Renal excretion of Digoxin is proportional to glomerular filtration rate and is largely independent of urine flow. In healthy volunteers with normal renal function, Digoxin has a half-life of 1.5 to 2 days. The half-life in anuric patients is prolonged to 3.5 to 5 days. Digoxin is not effectively removed from the body by dialysis, exchange transfusion, or during cardiopulmonary bypass because most of the drug is bound to tissue and does not circulate in the blood. Special PopulationsRace differences in Digoxin pharmacokinetics have not been formally studied. Because Digoxin is primarily eliminated as unchanged drug via the kidney and because there are no important differences in creatinine clearance among races, pharmacokinetic differences due to race are not expected. The clearance of Digoxin can be primarily correlated with renal function as indicated by creatinine clearance. The Cockcroft and Gault formula for estimation of creatinine clearance includes age, body weight, and gender. A table that provides the usual daily maintenance dose requirements of Digoxin tablets based on creatinine clearance (per 70 kg) is presented in the DOSAGE AND ADMINISTRATION section. Plasma Digoxin concentration profiles in patients with acute hepatitis generally fell within the range of profiles in a group of healthy subjects. Pharmacodynamic and Clinical EffectsThe times to onset of pharmacologic effect and to peak effect of preparations of Digoxin are shown in Table 2:
* Documented for ventricular response rate in atrial fibrillation, inotropic effects and electrocardiographic changes. † Depending upon rate of infusion. Hemodynamic EffectsDigoxin produces hemodynamic improvement in patients with heart failure. Short- and long-term therapy with the drug increases cardiac output and lowers pulmonary artery pressure, pulmonary capillary wedge pressure, and systemic vascular resistance. These hemodynamic effects are accompanied by an increase in the left ventricular ejection fraction and a decrease in end-systolic and end-diastolic dimensions. Chronic Heart FailureTwo 12-week, double-blind, placebo-controlled studies enrolled 178 (RADIANCE trial) and 88 (PROVED trial) patients with NYHA class II or III heart failure previously treated with oral Digoxin, a diuretic, and an ACE inhibitor (RADIANCE only) and randomized them to placebo or treatment with Digoxin tablets. Both trials demonstrated better preservation of exercise capacity in patients randomized to Digoxin. Continued treatment with Digoxin reduced the risk of developing worsening heart failure, as evidenced by heart failure-related hospitalizations and emergency care and the need for concomitant heart failure therapy. The larger study also showed treatment-related benefits in NYHA class and patients’ global assessment. In the smaller trial, these trended in favor of a treatment benefit. The Digitalis Investigation Group (DIG) main trial was a multicenter, randomized, double-blind, placebo-controlled mortality study of 6801 patients with heart failure and left ventricular ejection fraction ≤ 0.45. At randomization, 67% were NYHA class I or II, 71% had heart failure of ischemic etiology, 44% had been receiving Digoxin, and most were receiving concomitant ACE inhibitor (94%) and diuretic (82%). Patients were randomized to placebo or Digoxin tablets, the dose of which was adjusted for the patient’s age, sex, lean body weight, and serum creatinine (see DOSAGE AND ADMINISTRATION), and followed for up to 58 months (median 37 months). The median daily dose prescribed was 0.25 mg. Overall all-cause mortality was 35% with no difference between groups (95% confidence limits for relative risk of 0.91 to 1.07). Digoxin was associated with a 25% reduction in the number of hospitalizations for heart failure, a 28% reduction in the risk of a patient having at least one hospitalization for heart failure, and a 6.5% reduction in total hospitalizations (for any cause). Use of Digoxin was associated with a trend in reduction in time to all-cause death or hospitalization. The trend was evident in subgroups of patients with mild heart failure as well as more severe disease, as shown in Table 3. Although the effect on all-cause death or hospitalization was not statistically significant, much of the apparent benefit derived from effects on mortality and hospitalization attributed to heart failure.
* Number of patients with an event during the first 2 years per 1000 randomized patients. † Relative risk (95% confidence interval). ‡ DIG Ancillary Study. In situations where there is no statistically significant benefit of treatment evident from a trial’s primary endpoint, results pertaining to a secondary endpoint should be interpreted cautiously. Chronic Atrial FibrillationIn patients with chronic atrial fibrillation, Digoxin slows rapid ventricular response rate in a linear dose-response fashion from 0.25 to 0.75 mg/day. Digoxin should not be used for the treatment of multifocal atrial tachycardia. Indications and Usage for DigoxinHeart FailureDigoxin is indicated for the treatment of mild to moderate heart failure. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, Digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. Atrial FibrillationDigoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation. ContraindicationsDigitalis glycosides are contraindicated in patients with ventricular fibrillation or in patients with a known hypersensitivity to Digoxin. A hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to Digoxin. WarningsSinus Node Disease and AV BlockBecause Digoxin slows sinoatrial and AV conduction, the drug commonly prolongs the PR interval. The drug may cause severe sinus bradycardia or sinoatrial block in patients with pre-existing sinus node disease and may cause advanced or complete heart block in patients with pre-existing incomplete AV block. In such patients consideration should be given to the insertion of a pacemaker before treatment with Digoxin. Accessory AV Pathway (Wolff-Parkinson-White Syndrome)After intravenous Digoxin therapy, some patients with paroxysmal atrial fibrillation or flutter and a coexisting accessory AV pathway have developed increased antegrade conduction across the accessory pathway bypassing the AV node, leading to a very rapid ventricular response or ventricular fibrillation. Unless conduction down the accessory pathway has been blocked (either pharmacologically or by surgery), Digoxin should not be used in such patients. The treatment of paroxysmal supraventricular tachycardia in such patients is usually direct-current cardioversion. Use in Patients with Preserved Left Ventricular Systolic FunctionPatients with certain disorders involving heart failure associated with preserved left ventricular ejection fraction may be particularly susceptible to toxicity of the drug. Such disorders include restrictive cardiomyopathy, constrictive pericarditis, amyloid heart disease, and acute cor pulmonale. Patients with idiopathic hypertrophic subaortic stenosis may have worsening of the outflow obstruction due to the inotropic effects of Digoxin. PrecautionsUse in Patients with Impaired Renal FunctionDigoxin is primarily excreted by the kidneys; therefore, patients with impaired renal function require smaller than usual maintenance doses of Digoxin (see DOSAGE AND ADMINISTRATION). Because of the prolonged elimination half-life, a longer period of time is required to achieve an initial or new steady-state serum concentration in patients with renal impairment than in patients with normal renal function. If appropriate care is not taken to reduce the dose of Digoxin, such patients are at high risk for toxicity, and toxic effects will last longer in such patients than in patients with normal renal function. Use in Patients with Electrolyte DisordersIn patients with hypokalemia or hypomagnesemia, toxicity may occur despite serum Digoxin concentrations below 2 ng/mL, because potassium or magnesium depletion sensitizes the myocardium to Digoxin. Therefore, it is desirable to maintain normal serum potassium and magnesium concentrations in patients being treated with Digoxin. Deficiencies of these electrolytes may result from malnutrition, diarrhea, or prolonged vomiting, as well as the use of the following drugs or procedures: diuretics, amphotericin B, corticosteroids, antacids, dialysis, and mechanical suction of gastrointestinal secretions. Hypercalcemia from any cause predisposes the patient to digitalis toxicity. Calcium, particularly when administered rapidly by the intravenous route, may produce serious arrhythmias in digitalized patients. On the other hand, hypocalcemia can nullify the effects of Digoxin in humans; thus, Digoxin may be ineffective until serum calcium is restored to normal. These interactions are related to the fact that Digoxin affects contractility and excitability of the heart in a manner similar to that of calcium. Use in Thyroid Disorders and Hypermetabolic StatesHypothyroidism may reduce the requirements for Digoxin. Heart failure and/or atrial arrhythmias resulting from hypermetabolic or hyperdynamic states (e.g., hyperthyroidism, hypoxia, or arteriovenous shunt) are best treated by addressing the underlying condition. Atrial arrhythmias associated with hypermetabolic states are particularly resistant to Digoxin treatment. Care must be taken to avoid toxicity if Digoxin is used. Use in Patients with Acute Myocardial InfarctionDigoxin should be used with caution in patients with acute myocardial infarction. The use of inotropic drugs in some patients in this setting may result in undesirable increases in myocardial oxygen demand and ischemia. Use During Electrical CardioversionIt may be desirable to reduce the dose of Digoxin for 1 to 2 days prior to electrical cardioversion of atrial fibrillation to avoid the induction of ventricular arrhythmias, but physicians must consider the consequences of increasing the ventricular response if Digoxin is withdrawn. If digitalis toxicity is suspected, elective cardioversion should be delayed. If it is not prudent to delay cardioversion, the lowest possible energy level should be selected to avoid provoking ventricular arrhythmias. Laboratory Test MonitoringPatients receiving Digoxin should have their serum electrolytes and renal function (serum creatinine concentrations) assessed periodically; the frequency of assessments will depend on the clinical setting. For discussion of serum Digoxin concentrations, see DOSAGE AND ADMINISTRATION. Drug InteractionsPotassium-depleting diuretics are a major contributing factor to digitalis toxicity. Calcium, particularly if administered rapidly by the intravenous route, may produce serious arrhythmias in digitalized patients. Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum Digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result. Erythromycin and clarithromycin (and possibly other macrolide antibiotics) andtetracycline may increase Digoxin absorption in patients who inactivate Digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result. Propantheline and diphenoxylate, by decreasing gut motility, may increase Digoxin absorption. Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal Digoxin absorption, resulting in unexpectedly low serum concentrations. Rifampinmay decrease serum Digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of Digoxin. There have been inconsistent reports regarding the effects of other drugs (e.g., quinine, penicillamine) on serum Digoxin concentration. Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of Digoxin. Concomitant use of Digoxin and sympathomimetics increases the risk of cardiac arrhythmias. Succinylcholine may cause a sudden extrusion of potassium from muscle cells, and may thereby cause arrhythmias in digitalized patients. Although beta-adrenergic blockers or calcium channel blockers and Digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block. Due to the considerable variability of these interactions, the dosage of Digoxin should be individualized when patients receive these medications concurrently. Furthermore, caution should be exercised when combining Digoxin with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of Digoxin. Drug/Laboratory Test InteractionsThe use of therapeutic doses of Digoxin may cause prolongation of the PR interval and depression of the ST segment on the electrocardiogram. Digoxin may produce false positive ST-T changes on the electrocardiogram during exercise testing. These electrophysiologic effects reflect an expected effect of the drug and are not indicative of toxicity. Carcinogenesis, Mutagenesis, Impairment of FertilityThere have been no long-term studies performed in animals to evaluate carcinogenic potential, nor have studies been conducted to assess the mutagenic potential of Digoxin or its potential to affect fertility. PregnancyTeratogenic Effects–Pregnancy Category C.Animal reproduction studies have not been conducted with Digoxin. It is also not known whether Digoxin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Digoxin should be given to a pregnant woman only if clearly needed. Nursing MothersStudies have shown that Digoxin concentrations in the mother’s serum and milk are similar. However, the estimated exposure of a nursing infant to Digoxin via breast feeding will be far below the usual infant maintenance dose. Therefore, this amount should have no pharmacologic effect upon the infant. Nevertheless, caution should be exercised when Digoxin is administered to a nursing woman. Pediatric UseNewborn infants display considerable variability in their tolerance to Digoxin. Premature and immature infants are particularly sensitive to the effects of Digoxin, and the dosage of the drug must not only be reduced but must be individualized according to their degree of maturity. Digitalis glycosides can cause poisoning in children due to accidental ingestion. Geriatric UseThe majority of clinical experience gained with Digoxin has been in the elderly population. This experience has not identified differences in response or adverse effects between the elderly and younger patients. However, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, which should be based on renal function, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION). Adverse ReactionsIn general, the adverse reactions of Digoxin are dose-dependent and occur at doses higher than those needed to achieve a therapeutic effect. Hence, adverse reactions are less common when Digoxin is used within the recommended dose range or therapeutic serum concentration range and when there is careful attention to concurrent medications and conditions. Because some patients may be particularly susceptible to side effects with Digoxin, the dosage of the drug should always be selected carefully and adjusted as the clinical condition of the patient warrants. In the past, when high doses of Digoxin were used and little attention was paid to clinical status or concurrent medications, adverse reactions to Digoxin were more frequent and severe. Cardiac adverse reactions accounted for about one-half, gastrointestinal disturbances for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse reactions. However, available evidence suggests that the incidence and severity of Digoxin toxicity has decreased substantially in recent years. In recent controlled clinical trials, in patients with predominantly mild to moderate heart failure, the incidence of adverse experiences was comparable in patients taking Digoxin and in those taking placebo. In a large mortality trial, the incidence of hospitalization for suspected Digoxin toxicity was 2% in patients taking Digoxin tablets compared to 0.9% in patients taking placebo. In this trial, the most common manifestations of Digoxin toxicity included gastrointestinal and cardiac disturbances; CNS manifestations were less common. AdultsCardiacTherapeutic doses of Digoxin may cause heart block in patients with pre-existing sinoatrial or AV conduction disorders; heart block can be avoided by adjusting the dose of Digoxin. Prophylactic use of a cardiac pacemaker may be considered if the risk of heart block is considered unacceptable. High doses of Digoxin may produce a variety of rhythm disturbances, such as first-degree, second-degree (Wenckebach), or third-degree heart block (including asystole); atrial tachycardia with block; AV dissociation; accelerated junctional (nodal) rhythm; unifocal or multiform ventricular premature contractions (especially bigeminy or trigeminy); ventricular tachycardia; and ventricular fibrillation. Digoxin produces PR prolongation and ST segment depression which should not by themselves be considered Digoxin toxicity. Cardiac toxicity can also occur at therapeutic doses in patients who have conditions which may alter their sensitivity to Digoxin (see WARNINGS and PRECAUTIONS). GastrointestinalDigoxin may cause anorexia, nausea, vomiting, and diarrhea. Rarely, the use of Digoxin has been associated with abdominal pain, intestinal ischemia, and hemorrhagic necrosis of the intestines. CNSDigoxin can produce visual disturbances (blurred or yellow vision), headache, weakness, dizziness, apathy, confusion, and mental disturbances (such as anxiety, depression, delirium, and hallucination). OtherGynecomastia has been occasionally observed following the prolonged use of Digoxin. Thrombocytopenia and maculopapular rash and other skin reactions have been rarely observed. The following table summarizes the incidence of those adverse experiences listed above for patients treated with Digoxin tablets or placebo from two randomized, double-blind, placebo-controlled withdrawal trials. Patients in these trials were also receiving diuretics with or without angiotensin-converting enzyme inhibitors. These patients had been stable on Digoxin, and were randomized to Digoxin or placebo. The results shown in Table 4 reflect the experience in patients following dosage titration with the use of serum Digoxin concentrations and careful follow-up. These adverse experiences are consistent with results from a large, placebo-controlled mortality trial (DIG trial) wherein over half the patients were not receiving Digoxin prior to enrollment.
Infants and ChildrenThe side effects of Digoxin in infants and children differ from those seen in adults in several respects. Although Digoxin may produce anorexia, nausea, vomiting, diarrhea, and CNS disturbances in young patients, these are rarely the initial symptoms of overdosage. Rather, the earliest and most frequent manifestation of excessive dosing with Digoxin in infants and children is the appearance of cardiac arrhythmias, including sinus bradycardia. In children, the use of Digoxin may produce any arrhythmia. The most common are conduction disturbances or supraventricular tachyarrhythmias, such as atrial tachycardia (with or without block) and junctional (nodal) tachycardia. Ventricular arrhythmias are less common. Sinus bradycardia may be a sign of impending Digoxin intoxication, especially in infants, even in the absence of first-degree heart block. Any arrhythmia or alteration in cardiac conduction that develops in a child taking Digoxin should be assumed to be caused by Digoxin, until further evaluation proves otherwise. OverdosageTreatment of Adverse Reactions Produced by OverdosageDigoxin should be temporarily discontinued until the adverse reaction resolves. Every effort should also be made to correct factors that may contribute to the adverse reaction (such as electrolyte disturbances or concurrent medications). Once the adverse reaction has resolved, therapy with Digoxin may be reinstituted, following a careful reassessment of dose. Withdrawal of Digoxin may be all that is required to treat the adverse reaction. However, when the primary manifestation of Digoxin overdosage is a cardiac arrhythmia, additional therapy may be needed. If the rhythm disturbance is a symptomatic bradyarrhythmia or heart block, consideration should be given to the reversal of toxicity with Digoxin Immune Fab (Ovine) (see below), the use of atropine, or the insertion of a temporary cardiac pacemaker. However, asymptomatic bradycardia or heart block related to Digoxin may require only temporary withdrawal of the drug and cardiac monitoring of the patient. If the rhythm disturbance is a ventricular arrhythmia, consideration should be given to the correction of electrolyte disorders, particularly if hypokalemia (see below) or hypomagnesemia is present. Digoxin Immune Fab (Ovine) is a specific antidote for Digoxin and may be used to reverse potentially life-threatening ventricular arrhythmias due to Digoxin overdosage. Administration of PotassiumEvery effort should be made to maintain the serum potassium concentration between 4 and 5.5 mmol/L. Potassium is usually administered orally, but when correction of the arrhythmia is urgent and the serum potassium concentration is low, potassium may be administered cautiously by the intravenous route. The electrocardiogram should be monitored for any evidence of potassium toxicity (e.g., peaking of T waves) and to observe the effect on the arrhythmia. Potassium salts may be dangerous in patients who manifest bradycardia or heart block due to Digoxin (unless primarily related to supraventricular tachycardia) and in the setting of massive digitalis overdosage (see Massive Digitalis Overdosage subsection). Massive Digitalis OverdosageManifestations of life-threatening toxicity include ventricular tachycardia or ventricular fibrillation, or progressive bradyarrhythmias, or heart block. The administration of more than 10 mg of Digoxin in a previously healthy adult, or more than 4 mg in a previously healthy child, or a steady-state serum concentration greater than 10 ng/mL often results in cardiac arrest. Digoxin Immune Fab (Ovine) should be used to reverse the toxic effects of ingestion of a massive overdose. The decision to administer Digoxin Immune Fab (Ovine) to a patient who has ingested a massive dose of Digoxin but who has not yet manifested life-threatening toxicity should depend on the likelihood that life-threatening toxicity will occur (see above). Patients with massive digitalis ingestion should receive large doses of activated charcoal to prevent absorption and bind Digoxin in the gut during enteroenteric recirculation. Emesis or gastric lavage may be indicated especially if ingestion has occurred within 30 minutes of the patient’s presentation at the hospital. Emesis should not be induced in patients who are obtunded. If a patient presents more than 2 hours after ingestion or already has toxic manifestations, it may be unsafe to induce vomiting or attempt passage of a gastric tube, because such maneuvers may induce an acute vagal episode that can worsen digitalis-related arrhythmias. Severe digitalis intoxication can cause a massive shift of potassium from inside to outside the cell, leading to life-threatening hyperkalemia. The administration of potassium supplements in the setting of massive intoxication may be hazardous and should be avoided. Hyperkalemia caused by massive digitalis toxicity is best treated with Digoxin Immune Fab (Ovine); initial treatment with glucose and insulin may also be required if hyperkalemia itself is acutely life-threatening. Where can I get more information about Digoxin Digoxin injection ? We recommend to use www.Drugs.com Typical mistypes for Digoxin Digoxin injection sigoxin digoxin injection, xigoxin digoxin injection, cigoxin digoxin injection, figoxin digoxin injection, rigoxin digoxin injection, eigoxin digoxin injection, dugoxin digoxin injection, djgoxin digoxin injection, dkgoxin digoxin injection, dogoxin digoxin injection, d9goxin digoxin injection, d8goxin digoxin injection, difoxin digoxin injection, divoxin digoxin injection, diboxin digoxin injection, dihoxin digoxin injection, diyoxin digoxin injection, ditoxin digoxin injection, digixin digoxin injection, digkxin digoxin injection, diglxin digoxin injection, digpxin digoxin injection, dig0xin digoxin injection, dig9xin digoxin injection, digozin digoxin injection, digocin digoxin injection, digodin digoxin injection, digosin digoxin injection, digoxun digoxin injection, digoxjn digoxin injection, digoxkn digoxin injection, digoxon digoxin injection, digox9n digoxin injection, digox8n digoxin injection, digoxib digoxin injection, digoxim digoxin injection, digoxij digoxin injection, digoxih digoxin injection, digoxin sigoxin injection, digoxin xigoxin injection, digoxin cigoxin injection, digoxin figoxin injection, digoxin rigoxin injection, digoxin eigoxin injection, digoxin dugoxin injection, digoxin djgoxin injection, digoxin dkgoxin injection, digoxin dogoxin injection, digoxin d9goxin injection, digoxin d8goxin injection, digoxin difoxin injection, digoxin divoxin injection, digoxin diboxin injection, digoxin dihoxin injection, digoxin diyoxin injection, digoxin ditoxin injection, digoxin digixin injection, digoxin digkxin injection, digoxin diglxin injection, digoxin digpxin injection, digoxin dig0xin injection, digoxin dig9xin injection, digoxin digozin injection, digoxin digocin injection, digoxin digodin injection, digoxin digosin injection, digoxin digoxun injection, digoxin digoxjn injection, digoxin digoxkn injection, digoxin digoxon injection, digoxin digox9n injection, digoxin digox8n injection, digoxin digoxib injection, digoxin digoxim injection, digoxin digoxij injection, digoxin digoxih injection, digoxin digoxin unjection, digoxin digoxin jnjection, digoxin digoxin knjection, digoxin digoxin onjection, digoxin digoxin 9njection, digoxin digoxin 8njection, digoxin digoxin ibjection, digoxin digoxin imjection, digoxin digoxin ijjection, digoxin digoxin ihjection, digoxin digoxin inhection, digoxin digoxin innection, digoxin digoxin inmection, digoxin digoxin inkection, digoxin digoxin iniection, digoxin digoxin inuection, digoxin digoxin injwction, digoxin digoxin injsction, digoxin digoxin injdction, digoxin digoxin injrction, digoxin digoxin inj4ction, digoxin digoxin inj3ction, digoxin digoxin injextion, digoxin digoxin injevtion, digoxin digoxin injeftion, digoxin digoxin injedtion, digoxin digoxin injecrion, digoxin digoxin injecfion, digoxin digoxin injecgion, digoxin digoxin injecyion, digoxin digoxin injec6ion, digoxin digoxin injec5ion, digoxin digoxin injectuon, digoxin digoxin injectjon, digoxin digoxin injectkon, digoxin digoxin injectoon, digoxin digoxin inject9on, digoxin digoxin inject8on, digoxin digoxin injectiin, digoxin digoxin injectikn, digoxin digoxin injectiln, digoxin digoxin injectipn, digoxin digoxin injecti0n, digoxin digoxin injecti9n, digoxin digoxin injectiob, digoxin digoxin injectiom, digoxin digoxin injectioj, digoxin digoxin injectioh, igoxin digoxin injection, dgoxin digoxin injection, dioxin digoxin injection, digxin digoxin injection, digoin digoxin injection, digoxn digoxin injection, digoxi digoxin injection, digoxin digoxin injection, digoxin digoxin injection, digoxin igoxin injection, digoxin dgoxin injection, digoxin dioxin injection, digoxin digxin injection, digoxin digoin injection, digoxin digoxn injection, digoxin digoxi injection, digoxin digoxininjection, digoxin digoxin njection, digoxin digoxin ijection, digoxin digoxin inection, digoxin digoxin injction, digoxin digoxin injetion, digoxin digoxin injecion, digoxin digoxin injecton, digoxin digoxin injectin, digoxin digoxin injectio, idgoxin digoxin injection, dgioxin digoxin injection, diogxin digoxin injection, digxoin digoxin injection, digoixn digoxin injection, digoxni digoxin injection, digoxi n digoxin injection, digoxin digoxin injection, digoxin d igoxin injection, digoxin idgoxin injection, digoxin dgioxin injection, digoxin diogxin injection, digoxin digxoin injection, digoxin digoixn injection, digoxin digoxni injection, digoxin digoxi ninjection, digoxin digoxini njection, digoxin digoxin nijection, digoxin digoxin ijnection, digoxin digoxin inejction, digoxin digoxin injcetion, digoxin digoxin injetcion, digoxin digoxin injeciton, digoxin digoxin injectoin, digoxin digoxin injectino, ddigoxin digoxin injection, diigoxin digoxin injection, diggoxin digoxin injection, digooxin digoxin injection, digoxxin digoxin injection, digoxiin digoxin injection, digoxinn digoxin injection, digoxin digoxin injection, digoxin digoxin injection, digoxin ddigoxin injection, digoxin diigoxin injection, digoxin diggoxin injection, digoxin digooxin injection, digoxin digoxxin injection, digoxin digoxiin injection, digoxin digoxinn injection, digoxin digoxin injection, digoxin digoxin iinjection, digoxin digoxin innjection, digoxin digoxin injjection, digoxin digoxin injeection, digoxin digoxin injecction, digoxin digoxin injecttion, digoxin digoxin injectiion, digoxin digoxin injectioon, digoxin digoxin injectionn, etc.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||